ACKR3 and posterior cortical atrophy: To test the efficacy of CXCR7 inhibition using pharmacological inhibitors, we exploited alisertib, an AURKA inhibitor that has shown significant clinical benefit in a subset of patients with advanced PCa suggestive of AURKA and N-Myc overactivity in a recent clinical trial (28).